Splisense
Asaf Cohen has a diverse and extensive work experience. Asaf is currently working at Splisense, where they hold the role of VP CMC since November 2022. Prior to this, they worked at PolyPid from 2014, first as a Production Unit Manager responsible for managing the production activities and establishing GMP practices. Later, they became an Engineering Project Manager, overseeing the planning and construction of Polypid's Aseptic GMP Production Pilot Plant. In 2018, they took on the role of Production Manager, managing the Production and Warehouse team under GMP environment at PolyPid.
Before their time at PolyPid, Asaf worked at IBR from 2012 to 2014 as a Production Projects Manager, responsible for the entire production process of their products in the cosmetic, food, and pharmaceutical industries. Prior to that, they were a QA team member at Sigma Aldrich in 2012, where they were in charge of releasing raw materials for production and monitoring vital water systems.
Asaf's early work experience includes a role as a Pharmaceutical Engineering student at Teva Pharmaceuticals in 2011 and a position as Help Desk at StoreNext from 2007 to 2008.
Overall, Asaf Cohen possesses strong expertise in production management, GMP practices, and project management in the pharmaceutical and related industries.
Asaf Cohen pursued a Bachelor of Applied Science (B.A.Sc.) in Pharmaceutical Sciences at Jerusalem College of Engineering from 2008 to 2012. In 2016, they attended The College of Management Academic Studies to obtain a Master of Business Administration (MBA) with a concentration in Bio-Med, which they completed in 2017.
This person is not in any teams
This person is not in any offices
Splisense
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried.